The cancer treatment developer, co-founded by researchers from University of Chicago, has secured funding in a round co-led by Arix Bioscience and RTW Investments.

The developer of epigenetic medicine, based on Whitehead Institute research, pulled in funding through a round led by founding investor Flagship Pioneering.

Lyell Immunopharma co-led a series A round for the gene therapy developer, which was spun off by the corporate's co-founders.

The cancer therapy developer, which is commercialising research from University of Texas, has raised series B1 and B2 financing.

Lilly Asia Ventures participated in a series A-plus-plus round pushing the genome editing technology developer's total funding past $100m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

CWRU and UTMC-linked Rodeo Therapeutics is set to be acquired by Amgen for $55m in upfront and up to $666m in milestone payments.

Ohio State University spinout Entrada Therapeutics has pocketed $116m in a series B round.

MD Anderson Cancer Center spinout OncoResponse has added $40.6m to its coffers thanks to series C investors including Arch Venture Partners.

Achilles Therapeutics has raised more than $175m in its initial public offering on the Nasdaq Global Select Market.